- Report
- March 2024
- 189 Pages
Global
From €3244EUR$3,374USD£2,783GBP
€3605EUR$3,749USD£3,092GBP
- Report
- October 2023
- 172 Pages
Global
From €4712EUR$4,900USD£4,042GBP
- Report
- January 2024
- 143 Pages
Global
From €4087EUR$4,250USD£3,506GBP
- Report
- November 2023
- 184 Pages
Global
From €2404EUR$2,500USD£2,062GBP
- Report
- February 2023
- 126 Pages
Global
From €5721EUR$5,950USD£4,908GBP
- Report
- September 2019
- 160 Pages
Latin America
From €3990EUR$4,150USD£3,423GBP
- Report
- February 2021
- 125 Pages
Global
From €4567EUR$4,750USD£3,918GBP
- Report
- April 2023
- 246 Pages
Global
From €7212EUR$7,500USD£6,187GBP
- Report
- August 2022
- 118 Pages
Global
From €4327EUR$4,500USD£3,712GBP
- Report
- August 2022
- 120 Pages
Global
From €2404EUR$2,500USD£2,062GBP
Erythropoietin Stimulating Agents (ESAs) are a class of drugs used to treat anemia associated with chronic kidney and liver disorders. ESAs are recombinant proteins that stimulate the production of red blood cells in the body. They are used to treat anemia caused by chemotherapy, chronic kidney disease, and other conditions. ESAs are administered intravenously or subcutaneously, and can be used in combination with other treatments.
ESAs are generally well-tolerated, but can cause side effects such as hypertension, thrombosis, and an increased risk of stroke. The use of ESAs is regulated by the FDA, and the dosage and duration of treatment must be carefully monitored.
Some companies in the ESA market include Amgen, Johnson & Johnson, Roche, and Novartis. Show Less Read more
